Panacea Life Sciences Holdings, Inc.

Panacea Life Sciences Holdings, Inc., a seed to sale cannabinoid and nutraceutical manufacturer and research company, develops and produces natural pharmaceutical alternatives for consumers and pets. The company manufactures and sells softgels, gummies, tinctures, sublingual tablets, cosmetics, and other topicals. It is also involved in the personal protection equipment (PPE) business, including importing and selling PPE hand sanitizers and masks, as well as white label and contract manufacturing sales to other cannabinoid companies, raw material sales, and tolling arrangements. The company was incorporated in 2008 and is headquartered in Greenwood Village, Colorado.

Panacea Life Sciences Holdings, Inc. trades as PLSH on OTC. The company is classified in Healthcare / Drug Manufacturers - Specialty & Generic and reports in USD.

The current profile places the business in Drug Manufacturers - Specialty & Generic. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows $910,518 of revenue and -$416,675 of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Panacea Life Sciences Holdings, Inc. can be compared against peers such as Allied Corp., Aion Therapeutic Inc., Bhang Inc., Target Group Inc., Cann American Corp., Anything Technologies Media, Inc..

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $710,997, beta of 2.68, and return on equity of -7.7%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

PLSH currently shows total debt of $214,753 and beta of 2.68. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

Recent filings to review: SEC STAFF ACTION (2025-05-09 00:00:00), 15-12G (2024-07-16 00:00:00), 1-A (2024-06-11 00:00:00).

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.panacealife.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.